Nutrition and the prevention and treatment of cancer: Association of cytochrome P450 CYP1B1 with the role of fruit and fruit extracts

Integrative Cancer Therapies

Volumn 8, Issue 1, 2009, Pages 22-28

  Ware, William R ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b NONE   (Canada)

Author keywords

CYP1B1; Cytotoxins; Fruit extracts; Natural cancer therapy; Phytochemicals

Indexed keywords

CYTOCHROME P450 1B1; DMU 135; PHORTESS; PLANT MEDICINAL PRODUCT; RESVERATROL; SALVESTROL; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CATALYSIS; CYTOTOXICITY; DNA POLYMORPHISM; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FOOD INTAKE; FRUIT; HUMAN; HYDROXYLATION; NONHUMAN; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; VEGETABLE;

ARYL HYDROCARBON HYDROXYLASES; DIET; FRUIT; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PLANT EXTRACTS; TUMOR MARKERS, BIOLOGICAL; VEGETABLES;

EID: 61849107104     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735408328573     Document Type: Review

References (43)

1. Murray GI, Melvin WT, Greenlee WF, Burke MD Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol. 2001 ; 41: 297-316.
2. Tan HL, Butler PC, Burke MD, Potter GA Salvestrols: a new perspective in nutritional research. J Orthomol Med. 2008 ; 22: 40-47.
3. Karlgren M., Gomez A., Stark K., et al. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun. 2006 ; 341: 451-458.
4. Peter GF, Chun YJ, Kim D., Gillam EM, Shimada T. Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res. 2003 ;523- 524: 173-182.
5. Potter GA, Patterson LH, Wanogho E., et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer. 2002 ; 86: 774-778. pp. 777
6. Yager JD, Davidson NE Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006 ; 354: 270-282.
7. Belous AR, Hachey DL, Dawling S., Roodi N., Parl FF Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation. Cancer Res. 2007 ; 67: 812-817.
8. Bruno RD, Njar VC Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem. 2007 ; 15: 5047-5060.
9. Cheung YL, Kerr AC, McFadyen MC, Melvin WT, Murray GI Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. Cancer Lett. 1999 ; 139: 199-205.
10. Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 1997 ; 57: 3026-3031.
11. Carnell DM, Smith RE, Daley FM, et al. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys. 2004 ; 58: 500-509.
12. Gibson P., Gill JH, Khan PA, et al. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther. 2003 ; 2: 527-534.
13. Downie D., McFadyen MC, Rooney PH, et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 2005 ; 11: 7369-7375.
14. Barnett JA, Urbauer DL, Murray GI, Fuller GN, Heimberger AB Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res. 2007 ; 13: 3559-3567.
15. Spivack SD, Hurteau GJ, Reilly AA, Aldous KM, Ding X., Kaminsky LS CYP1B1 expression in human lung. Drug Metab Dispos. 2001 ; 29: 916-922.
16. McFadyen MC, Melvin WT, Murray GI Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br J Cancer. 2004 ; 91: 966-971.
17. McFadyen MC, Cruickshank ME, Miller ID, et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer. 2001 ; 85: 242-246.
18. Maecker B., Sherr DH, Vonderheide RH, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood. 2003 ; 102: 3287-3294.
19. Muskhelishvili L., Thompson PA, Kusewitt DF, Wang C., Kadlubar FF In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem. 2001 ; 49: 229-236.
20. Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, Sutter TR Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol. 2004 ; 199: 210-219.
21. Sissung TM, Price DK, Sparreboom A., Figg WD Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res. 2006 ; 4: 135-150.
22. Ding X., Kaminsky LS Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2003 ; 43: 149-173.
23. McFadyen MC, Breeman S., Payne S., et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem. 1999 ; 47: 1457-1464.
24. Sissung TM, Price DK, Sparreboom A., Figg WD Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res. 2006 ; 4: 135-150.
25. McFadyen MC, Melvin WT, Murray GI Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther. 200 ; 3: 363-371.
26. Tsuchiya Y., Nakajima M., Takagi S., Taniya T., Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006 ; 66: 9090-9098.
27. Vainio H., Weiderpass E. Fruit and vegetables in cancer prevention. Nutr Cancer. 2006 ; 54: 111-142.
28. Juranic Z., Zizak Z. Biological activities of berries: from antioxidant capacity to anti-cancer effects. Biofactors. 2005 ; 23: 207-211.
29. Seeram NP Berry fruits for cancer prevention: current status and future prospects. J Agric Food Chem. 200 ; 56: 630-635.
30. Kundu JK, Surh YJ Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. In press.
31. Chang TKH, Chen J., Lee WBK. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 ; 299: 874-882.
32. Potter GA The role of CYP1B1 as a tumour suppressor enzyme. Br J Cancer. 2002 ; 86: S12.
33. Schaefer BA, Tan H., Burke MD, Potter GA Nutrition and cancer: salvestrol case studies. J Orthomol Med. 2008 ; 22: 177.
34. Magee JB, Smith BJ Resveratrol content of muscadine berries is affected by disease control spray program. HortScience. 2008 ; 37: 251.
35. Daniel O., Meier MS, Schlatter J., Frischknecht P. Selected phenolic compounds in cultivated plants: ecologic functions, health implications, and modulation by pesticides. Environ Health Perspect. 1999 ; 107 (suppl 1). 109-114.
36. Sale S., Verschoyle RD, Boocock D., et al. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′- tetramethoxystilbene. Br J Cancer. 2004 ; 90: 736-744.
37. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem. 2004 ; 279: 23847-23850.
38. Tokizane T., Shiina H., Igawa M., et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res. 2005 ; 11: 5793-5801.
39. Chokkalingam AP, Nyren O., Johansson JE, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer. 2003 ; 98: 1727-1734.
40. Chang BL, Zheng SL, Isaacs SD, et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer. 2003 ; 89: 1524-1529.
41. Chun YJ, Kim S. Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents. Med Res Rev. 2003 ; 23: 657-668.
42. Kvistborg P., Hadrup SR, Svane IM, Andersen MH, Straten PT Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients. Hum Immunol. 2008 ; 69: 266-272.
43. Sale S., Tunstall RG, Ruparelia KC, et al. Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse. Invest New Drugs. 2006 ; 24: 459-464.